BICYCLE THERAPEUTICS PLC (BCYC) stock: key figures, P/E, revenue and dividend
Health Care · United Kingdom · ISIN US0887861088
BICYCLE THERAPEUTICS PLC financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 72.59 m USD |
| Gross profit | -156.50 m USD |
| Operating income | -247.07 m USD |
| EBIT | -218.60 m USD |
| Net income | -218.96 m USD |
| Diluted EPS – continuing operations | -3.16 USD |
Full history since 2016, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About BICYCLE THERAPEUTICS PLC
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing. In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that are in preclinical trial targeting radiopharmaceutical. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Ionis Pharmaceuticals, Inc.; Genentech, Inc; and AstraZeneca AB. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
More stocks
- NeoPharm CO. LTD (092730.KQ)
- MC Group Public Company Limited (MC.BK)
- Addcn Technology Co Ltd (5287.TWO)
- Holidaycheck Group (HOC.HM)
- Chongqing Wanli New Energy Co Ltd (600847.SS)
- Cruzeiro do Sul Educacional S.A (CSED3.SA)
- PRECISION BIOSCIENCES INC (DTIL)
- Hongda High-Tech Holding Co Ltd (002144.SZ)
- Global IBO Group Ltd (GIBO)
- Springsnow Food Group Co Ltd (605567.SS)
- Shanghai Xintonglian Packaging Co Ltd (603022.SS)
- Hangzhou Chuhuan Science & Technology Co. Ltd. A (001336.SZ)
Not investment advice. All data without warranty, price as of 05.11.2026. Details in the risk notice.